Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines

Anesth Analg. 2010 Mar 1;110(3):934-41. doi: 10.1213/ANE.0b013e3181c95cfa.

Abstract

Background: Recent data indicate that ketamine exerts antiinflammatory actions. However, little is known about the signaling mechanisms involved in ketamine-induced immune modulation. In this study, we investigated the effects of ketamine on lipopolysaccharide-induced activation of transcription factors activator protein 1 (AP-1) and nuclear factor-kappaB (NF-kappaB) in human leukocyte-like cell lines and in human blood neutrophils.

Methods: Electric mobility shift assays were used to investigate ketamine's effects on nuclear binding activity of both transcription factors in U937 cells, and a whole blood flow cytometric technique was used for AP-1 and NF-kappaB determination in leukocytes. Cell lines with different expression patterns of opioid and N-methyl-D-aspartate receptors were used for reverse transcription-polymerase chain reaction to investigate receptors involved in ketamine signaling. Ketamine's effect on interleukin-8 production was assessed in a whole blood assay.

Results: Ketamine inhibited both transcription factors in a concentration-dependent manner. These effects did not depend on opiate or N-methyl-D-aspartate receptors. Ketamine also reduced interleukin-8 production in whole blood and expression of CD11b and CD16 on neutrophils.

Conclusion: The immunoinhibitory effects of ketamine are at least in part caused by inhibition of transcription factors NF-kappaB and AP-1, which regulate production of proinflammatory mediators. However, signaling mechanisms different from those present in the central nervous system are responsible for ketamine-mediated immunomodulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / pharmacology*
  • CD11b Antigen / metabolism*
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Electrophoretic Mobility Shift Assay
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • GPI-Linked Proteins
  • HL-60 Cells
  • Humans
  • Interleukin-8 / metabolism*
  • Ketamine / pharmacology*
  • Leukocytes / drug effects*
  • Leukocytes / immunology
  • Leukocytes / metabolism
  • Lipopolysaccharides / pharmacology
  • Male
  • NF-kappa B / metabolism*
  • Neutrophils / drug effects
  • Neutrophils / immunology
  • Neutrophils / metabolism
  • Receptors, IgG / metabolism*
  • Receptors, N-Methyl-D-Aspartate / genetics
  • Receptors, Opioid, mu / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • Transcription Factor AP-1 / metabolism*
  • U937 Cells
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • CD11b Antigen
  • CXCL8 protein, human
  • FCGR3B protein, human
  • GPI-Linked Proteins
  • ITGAM protein, human
  • Interleukin-8
  • Lipopolysaccharides
  • NF-kappa B
  • Receptors, IgG
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Opioid, mu
  • Transcription Factor AP-1
  • lipopolysaccharide, E. coli O26-B6
  • Ketamine